Intrahepatic cholangiocarcinoma (ICC) is a rare type of liver cancer that forms in the bile ducts within the liver. ICC develops from the epithelial cells that line the small bile ducts inside the liver. Symptoms of ICC include jaundice, abdominal pain, weight loss and fever. Diagnosis of ICC involves blood tests, imaging tests and biopsy. Treatment options for ICC include surgery, radiation therapy, chemotherapy and liver transplant. However, survival rates remain low as ICC is often detected at an advanced stage. The Global Intrahepatic Cholangiocarcinoma Market is estimated to be valued at US$ 185 million in 2024 and is expected to exhibit a CAGR of 7.9% over the forecast period 2024 to 2031. Key Takeaways
Key players operating in the Intrahepatic Cholangiocarcinoma are Bayer AG, Bristol-Myers Squibb, Boston Pharmaceuticals, F. Hoffmann-La Roche AG, and Merck & Co. The growing prevalence of liver diseases and rising cancer incidence rates are major factors driving the growth of the ICC market. According to the statistics by WHO, nearly 1 million new liver cancer cases are reported globally each year. Additionally, lifestyle changes and obesity have increased the risk of developing ICC. North America dominates the global ICC market due to high healthcare spending and increasing research and development activities in the region. However, Asia Pacific is expected to exhibit lucrative growth during the forecast period owing to growing patient population, rising awareness and improving healthcare infrastructure in developing nations. Market key trends
Precision medicine is emerging as a key trend in the ICC treatment landscape. Several targeted drugs and immunotherapies are being studied to improve clinical outcome in ICC patients. For example, FGFR inhibitors such as pemigatinib that block FGFR2 fusion proteins show promising results in clinical trials. Combination therapy approaches using immune checkpoint inhibitors along with chemotherapeutic agents are also being evaluated for ICC. With growing understanding of ICC pathogenesis, more personalized treatment options centered around molecular profiling are expected to enter the market.
Porter's Analysis Threat of new entrants: Low capital requirements and established brand loyalty reduce threats of new players. Bargaining power of buyers: Customers have limited bargaining power due to specialized nature of treatment and diagnostics. Bargaining power of suppliers: Suppliers have moderate bargaining power due to availability of substitutes and regulatory barriers. Threat of new substitutes: Low threat as limited alternative for diagnosis and treatment of cholangiocarcinoma exist. Competitive rivalry: Intense competition exists among established players to gain higher market share through innovative products and service offerings. Geographical Regions North America dominates the intrahepatic cholangiocarcinoma market in terms of value owing to rising incidences, growing awareness, and availability of advanced therapies. Asia Pacific exhibits fastest growth over the forecast period driven by improving healthcare infrastructure, rising healthcare expenditure, and increasing focus toward cancer care in China, India, and Japan.
What Are The Key Data Covered In This Intrahepatic Cholangiocarcinoma Therapeutics Market Report?
:- Market CAGR throughout the predicted period
:- Comprehensive information on the aspects that will drive the Cardiac ablation devices's growth between 2024 and 2031.
:- Accurate calculation of the size of the Intrahepatic Cholangiocarcinoma Therapeutics and its contribution to the market, with emphasis on the parent market
:- Realistic forecasts of future trends and changes in consumer behaviour
:- Intrahepatic Cholangiocarcinoma Therapeutics Industry Growth in North America, APAC, Europe, South America, the Middle East, and Africa
:- A complete examination of the market's competitive landscape, as well as extensive information on vendors
:- Detailed examination of the factors that will impede the expansion of Intrahepatic Cholangiocarcinoma Therapeutics vendors
Writer, has a strong foothold in the market research industry. She specializes in writing well-researched
About Author:
Ravina Pandya, Content Writer, has a strong foothold in the market research industry. She specializes in writing well-researched articles from different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc.
*Note: 1. Source: Coherent Market Insights, Public sources, Desk research 2. We have leveraged AI tools to mine information and compile it
